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Plasma and urinary oestrogens in breast cancer patients on treatment
with 4-hydroxyandrostenedione
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Summary Plasma and urinary oestrogens were measured in nine breast cancer patients (eight postmenopausal
women and one man) before and during treatment with the aromatase inhibitor 4-hydroxyandrostenedione.
Urinary oestrogens were measured by using a highly specific GC-MS method. Plasma levels of oestrone,
oestradiol and oestrone sulphate were suppressed by 66.6% (± 3.6%), 57.7% (± 5.1%) and 51.8% (± 6.4%)
respectively (P<0.005 for all). Twenty-four hour urinary excretion of total oestrogens, oestradiol, oestriol,
2-hydroxyoestrone, 16&x-hydroxyoestrone and the minor metabolites 16p - and 15a-hydroxyoestrone were all
suppressed by mean values ranging from 60% to 82%, (oestradiol: P<0.025, otherwise P<0.005). There were
no significant changes in the ratios between the different plasma oestrogens. The finding of sustained plasma
and urinary oestrogens at 20-40% compared to their control levels indirectly support a hypothesis of
alternative oestrogen sources in postmenopausal breast cancer patients on treatment with 4-hydroxyandro-
stenedione.
The aim of contemporary endocrine treatment of advanced
breast cancer is to reduce oestrogen stimulation to the
tumour cell. This could be achieved either by blocking
oestrogen action at the receptor level with antioestrogens or
by reducing the oestrogen supply to the tumour cell.
The major pathway of oestrogen production in postmeno-
pausal women is peripheral conversion (aromatisation) of
circulating androstenedione (A) into oestrone (Oel) (Grodin
et al., 1973). Aromatase inhibition is a successful approach to
achieve plasma oestrogen suppression and tumour shrinkage
in postmenopausal women suffering from breast cancer. The
'classic' aromatase inhibitor, aminoglutethimide (Orimetene®),
has been in clinical use for more than two decades (L0nning
& Kvinnsland, 1988). The toxic side effects caused by this
drug has prompted the development of new and more selec-
tive aromatase inhibitors (L0nning et al., 1990).
4-Hydroxyandrostenedione (Formestanee, Ciba-Geigy) is a
second generation aromatase inhibitor (Brodie et al., 1977),
first reported to cause tumour shrinkage in breast cancer
patients in 1984 (Coombes et al., 1984). In contrast to
aminoglutethimide, 4-hydroxyandrostenedione seems to act
specifically on the aromatase enzyme (Brodie et al., 1981;
Dowsett et al., 1989). The drug causes few side-effects, and
results from phase I and II trials including more than 500
patients have revealed an overall response rate of 26%
among unselected patients (L0nning, 1992).
The biochemical action of aromatase inhibitors in vivo is
still incompletely understood. Different aromatase inhibitors
like aminoglutethimide, 4-hydroxyandrostenedione (Formes-
tane®, Ciba-Geigy) and CGS 16949 (Fadrazole®, Ciba-Geigy)
inhibit aromatisation by 82-98% (Dowsett et al., 1985;
Jones et al., 1992; L0nning et al., 1991; Reed et al., 1990;
Santen et al., 1978 ). Despite this, several investigators have
reported sustained plasma oestrogens at about 30-50% of
their control values in treated patients (Dowsett et al., 1989;
Dowsett et al., 1990; L0nning et al., 1989b; Santen et al.,
1982; Santen et al., 1989; Vermeulen et al., 1983). Some
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aromatase inhibitors may act on plasma oestrogen by mech-
anisms other than aromatase inhibition; aminoglutethimide
has been shown to stimulate the metabolism of plasma oes-
trone sulphate (Oe,S) by enhancing the production of 16a-
hydroxylated metabolites (16&-hydroxyoestrone and oestriol)
(L0nning et al., 1987; L0nning et al., 1989a; L0nning &
Skulstad, 1989).
So far most studies have evaluated the influence of aroma-
tase inhibitors on plasma oestrogens. However, due to the
low levels of plasma oestrogens in patients on treatment with
aromatase inhibitors, these steroids can be measured with
RIA methods only, in which case there is a risk of non-
specific interactions in the assay. About 60-70% of the
oestrogen metabolites are excreted in the urine (Fishman et
al., 1966; Zumoff et al., 1968), and the concentration of
urinary oestrogen metabolites is about 100 times the concen-
tration of plasma oestrogens. These urinary oestrogen meta-
bolites may therefore be measured by highly specific GC-MS
methods (Fotsis & Adlercreutz, 1987).
To our knowledge neither plasma OeIS nor urinary oestro-
gen metabolites have previously been reported in patients
treated with 4-hydroxyandrostenedione. This study was
designed to test whether sustained plasma Oel and Oe2 levels
in breast cancer patients treated with 4-hydroxyandrostene-
dione are accompanied by sustained plasma Oe1S and
urinary oestrogen metabolite excretion. By comparing plasma
and urinary oestrogen suppression, non specific interactions
in the RIA assay or alteration in oestrogen disposition not
related to aromatase inhibition might be reflected in conflict-
ing results.
Patients and methods
Patients
Nine patients with advanced breast cancer (one man and
eight postmenopausal women) who were to receive 4-
hydroxyandrostenedione because of progressive disease were
included in this study. All gave their verbal informed con-
sent. The mean age was 72 years (range 62 to 79 years). No
patients were smokers, and none of them received any other
hormonal treatment or drugs known to influence drug meta-
bolism. The liver enzymes and plasma creatinine were within
the normal range in all patients, indicating normal liver and
renal function.
All patients had previously been treated with two or more
different endocrine regimens (range two to eight, median
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three regimens). Any previous hormonal therapy was termin-
ated at least 4 weeks before commencing 4-hydroxyandro-
stenedione. Two patients had received previous treatment
with aminoglutethimide, in which case aminoglutethimide
was terminated 4 and 8 weeks before commencing on 4-
hydroxyandrostenedione.
Treatment schedule and samplingprotocol
All patients had i.m. injections of 4-hydroxyandrostenedione
250 mg. The injections were given weekly for the first 6
weeks, thereafter at 2-weekly intervals. Blood and urine
sampling were performed before commencing on 4-hydroxy-
androstenedione and after 36 to 80 days on treatment. The
time interval from the last injection of 4-hydroxyandro-
stenedione to blood and urine collection in the on-treatment
test situation ranged from 2 to 13 days with a median of 7
days.
Twenty-four hour urine was collected in dark glass bottles
containing ascorbic acid (final concentration >4 g 1') to
prevent the catechol-oestrogens from undergoing oxidation
(Gelbke, 1973). The urine was pooled, one aliquot was
obtained for urinary creatinine measurement, and two ali-
quots of 50 ml were frozen and stored at - 20'C until pro-
cessing.
Heparinised blood samples were obtained on the morning
of the urine collection period between 8 a.m. and 9 a.m. after
an overnight fast. Plasma was separated by centrifugation
and stored at - 20°C until processing.
Analytical methods
Plasma oestrogens were measured by modification of RIA
methods previously described (Dowsett et al., 1987; L0nning
et al., 1989a). The sensitivity limit for Oel, Oe2 and Oe1S was
2.1 pM, 6.3 pM and 25.9 pM respectively, and the Cv within
assay were 4.4% 3.9% and 6%.
The analytical method for the determination of the urinary
oestrogen profile based on capillary gas chromatography-
mass spectrometry (GC/MS) in the selected ion monitoring
(SIM) mode has been published (Fotsis & Adlercreutz, 1987).
A significant improvement in the accuracy and precision of
the method included the addition of deuterated (d5)ethoxime
derivatives (Wiihala et al., 1987) of all ketonic oestrogens as
internal standards immediately after hydrolysis of the urine
extract. In this way stable-isotope dilution mass spectrometry
could be used for all ketonic oestrogens. The final determina-
tion is carried out using a Hewlett Packard 5995B quadruple
instrument equipped with a 0.2 mm x 12.4 m bonded phase
BP 1 (equivalent to silicone SE-30) capillary silica column
directly connected to ion source. The coefficients of variation
for all fractions and other details regarding the reliability of
the procedure have been published (Fotsis & Adlercreutz,
1987; Bannwart et al., 1988). The following oestrogens were
determined: Oestron e (Oel), Oestradiol (Oe2), 2-hydroxy-
oestrone (2-OHOel), 2-hydroxy-oestradiol (2-OHOe2), 2-
methoxyoestrone (2-MeOOel), 4-hydroxyoestrone (4-OHOel),
oestriol (Oe3), 16a-hydroxyoestrone (16cc-OHOel), l6,-
hydroxy-oestrone (16,-OHOel), 15a-hydroxyoestrone (15-
OHOel) and 16-keto-oestradiol (16-KetoOe2).
Creatinine in urine and serum was measured by the
method of Jaffe. As none of the patients had any significant
change in plasma creatinine values during the investigation
period, it was found feasible to use the creatinine clearance
value as a 'recovery standard' for urine collection. Thus, to
correct for any difference in urine losses between the two test
situations, the amount of urinary oestrogens excreted was
calculated using the ratio between the highest and the actual
creatinine clearance for each patient as a correction fac-
tor.
Statistical methods
Plasma and urinary oestrogen levels before and during treat-
ment were compared using the Wilcoxon Matched Pair
Signed Rank Test. All P-values were expressed as two-tailed.
Results
Plasma oestrogens
Plasma oestrogen levels before and during treatment are
given in Table I and Figure 1. Treatment with 4-hydroxy-
androstenedione suppressed plasma levels of Oel, Oe2 and
Oe1S in all patients (P<0.005). The mean percentage of
suppression (± s.e.m.) was 66.6% (± 3.6%), 57.7% (+
5.1%) and 51.8% (± 6.4%) for Oel, Oe2 and OejS respec-
tively. While the Oej/Oe1S ratio decreased in eight of nine
patients, this was not of statistical significance (a ratio of
0.213 ± 0.031 and 0.163 ± 0.027 before and during treatment
respectively, P = 0.080). There was no change in the Oe2/
Oe,S ratio (0.042 ± 0.006 before and 0.037 ± 0.004 during
treatment, P> 0.20), but a small increase in the O2/Oel ratio
(mean value before and during treatment 0.212 ± 0.022 and
0.260 ± 0.029 respectively; P = 0.054.)
Urinary oestrogens
Urinary excretion of total oestrogens and the different
oestrogen metabolites is shown in Table II and in Figure 2a
and 2b. The results may be summarised as follows:
(1) Urinary excretion of total oestrogens was suppressed
by a mean value of 66%.
(2) All urinary metabolites except for 2-OHOe2 and 4-
OHOe, were significantly suppressed (mean values of
suppression ranging from 60% to 82%). The urinary
concentration of 4-OHOel was below the sensitivity
limit of the assay in the control situation. Thus, the
result obtained for this metabolite should be inter-
preted with caution.
(3) No significant alterations in the ratio of the 16a-
hydroxylated metabolites (16a-OHOel and Oe3) or 2-
OHOel relative to Oel were found.
Comparison ofplasma and urinary oestrogen suppression
The relative suppressions of urinary and plasma oestrogens
were of the same magnitude. A suppression of total urinary
oestrogen by 66% (± 5.6%) corresponds well to a suppres-
sion of plasma Oel, Oe2 and OejS of 66.6 (± 3.6%), 57.7%
(± 5.1%) and 51.8% (± 6.4%) respectively.
Table I Mean values in pmol 1-' (± s.e.m.) and mean percentual suppression
( s.e.m.) before and during treatment with 4-hydroxyandrostenedione
Before During % suppression P
Plasma Oe2 15.4 3.4 5.5 0.7 57.8 5.1 <0.005
Plasma Oel 70.6 10.8 21.0 1.5 66.6 3.6 <0.005
Plasma OelS 456.0 131.1 197.0 83.5 51.8 6.4 <0.005
Ratio Oe2/OelS 0.042 0.006 0.037 0.004 ns
Ratio Oe2/Oel 0.212 ± 0.022 0.260 ± 0.029 0.054
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P-Oe2 previously reported by others (Dowsett et al., 1989; Reed et
al., 1990). To our knowledge, plasma OeIS and urinary
oestrogen metabolite excretion have not been measured in
patients on treatment with 4-hydroxyandrostenedione pre-
viously. Oestrone sulphate has been suggested to play an
important role as an oestrogen source to the tumour cell
(Santner et al., 1986; Pasqualini et al., 1989), and the
influence of aromatase inhibitors on plasma Oe,S levels may
be of significant biological importance.
Aromatase is a key enzyme in postmenopausal oestrogen
synthesis. Current opinion is that peripheral aromatisation of
circulating A and testosterone (T) into Oel and Oe2 respec-
tively accounts for total postmenopausal oestrogen-synthesis.
P-OelS
P-Oel
.5
CV
Figure 1 Individual plasma levels of oestradiol P-Oe2), oestrone
(P-Oel) and oestrone sulphate (P-Oe,S) before and during treat-
ment in 9 breast cancer patients (8 postmenopausal women: 0,
and 1 man: U) treated with 250 mg 4-hydroxyandrostenedione
i.m. fortnightly.
Discussion
Plasma levels of Oel, Oe2 and Oe,S obtained in our patients
before treatment were in the same range as previously re-
ported by us and others for postmenopausal breast cancer
patients but plasma Oe,S was in the low normal range
(Dowsett et al., 1989; Lonning et al., 1989b; Vermeulen et al.,
1983). The amount of different urinary oestrogen metabolites
excreted during 24h was in the same range as previously
reported in breast cancer patients (Aldercreutz et al.,
1991).
The relative suppression of plasma Oel and Oe2 obtained
by 4-hydroxyandrostenedione was of the same magnitude as
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Figure 2a,b Twenty-four hours urinary excretion of the major
oestrogen metabolites and total urinary oestrogens before and
during treatment in 9 breast cancer patients (8 postmenopausal
women: 0, and 1 man: *) treated with 250 mg 4-hydroxyandro-
stenedione i.m. fortnightly. U-Oe2 = urinary oestradiol, U-Ge, =
urinary oestrone, U-Oe3 = urinary oestriole. Total U-Oe = total
urinary oestrogen, 2-OHOe, = 2-hydroxyoestrone and 16m-
OHOe, = 16m-hydroxyoestrone.
Table II Mean values in nmol 24 h-' (± s.e.m.) and mean percentual suppression
( s.e.m.) of 24 h urinary metabolites before and during treatment with
4-hydroxyandrostenedione
Metabolite Before During % suppression P
2-OHOel 4.64 1.47 1.09 0.25 70.8 ± 5.2 <0.005
4-OHOel 0.54 i 0.15 0.43 ± 0.12 13.5 ± 16.0 >0.2
2-OHOe2 2.27 ± 0.39 1.44 + 0.37 14.2 ± 39.2 >0.1
Oe2 1.57 0.27 0.44±0.11 59.7± 17.4 <0.025
Oel 5.86 1.26 1.90 0.35 63.6 5.3 <0.005
2-methoxy0el 1.13 ± 0.22 0.28 ± 0.07 72.9 ± 4.2 <0.005
16-OHOel 1.91 ± 0.26 0.42 ± 0.07 78.1 ± 2.3 <0.005
15-OHOel 0.35 ± 0.12 0.10 ± 0.02 60.2 ± 8.2 <0.005
16-OHOel 1.30 ± 0.33 0.23 ± 0.12 81.8 ± 7.9 <0.005
16-ketoOe2 1.04 ± 0.17 0.23 ± 0.09 74.3 ± 9.5 <0.005
Oe3 7.62 1.90 1.92 0.41 68.3 ± 8.3 <0.005
Total oestrogens 28.24 ± 4.48 8.47 ± 1.37 66.2 ± 5.6 <0.005
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Aromatase inhibition is a successful treatment approach in
postmenopausal breast cancer. Treatment with different
aromatase inhibitors like aminoglutethimide, 4-hydroxyan-
drostenedione and CGS 16949A all cause effective suppres-
sion of plasma oestrogens (Santen et al., 1982; Santen et al.,
1989; Dowsett et al., 1989; Dowsett et al., 1990) and clinical
responses comparable to what may be expected from the
most effective forms of endocrine treatment like antioestro-
gens and high dose progestins (L0nning et al., 1992). Thus,
aromatase inhibitors differ significantly from other drugs
investigated as hormone suppressors in postmenopausal
breast cancer. Glucocorticoids, ketoconazole and trilostane
all suppress adrenal steroid synthesis, cause a modest sup-
pression of plasma oestrogens, and produce clinical responses
in a small number of patients (Harris et al., 1988; Harris et
al., 1984; Beardwell et al., 1983; Coombes et al., 1985; Wil-
liams et at., 1987). The results obtained with these drugs
compared with aromatase inhibitors indirectly suggest a dose
response relationship between plasma oestrogen suppression
and the chance of achieving a clinical response in post-
menopausal breast cancer patients. Accordingly, a major goal
is to achieve maximal oestrogen suppression.
The efficacy of an aromatase inhibitor may be assessed in
different ways. One approach is to measure in vivo aromatase
inhibition by use of isotope tracer infusions (Jacobs et al.,
1991), another approach is to measure the degree of plasma
oestrogen suppression. A major problem is to explain the
inconsistency of the results obtained with these different
methods and to interpret the finding of sustained plasma
oestrogens despite subtotal aromatase inhibition. There are
two possible explanations for these findings. First, they may
be due to technical flaws in the tracer infusion studies or with
plasma oestrogen analysis. Second, they indicate some alter-
native sources of plasma oestrogens in patients on treatment
with aromatase inhibitors.
Considering the first possibility, tracer studies have re-
vealed a >90% inhibition of the conversion of circulating
androstenedione into oestrone during treatment with 4-
hydroxyandrostenedione (Jones et al., 1992; Reed et al.,
1990) as well as with other aromatase inhibitors (L0nning et
al., 1991; McNeill et al., 1992; Santen et al., 1978). These
methods are sensitive enough to detect aromatase inhibition
down to 98-99% (Jacobs et al., 1991). Any non-specific
interaction in the chromatograms may be expected to cause
an underestimation of the degree of inhibition. Thus, it is not
likely that these studies may have overrated the efficacy of
these drugs. While the possibility of non-specific interactions
in the radioimmunoassays is a more likely event, our finding
of an internal consistency between the relative suppression of
plasma oestrogens measured by RIA techniques and the
suppression of urinary oestrogen metabolites measured by a
specific GC-MS method provides indirect evidence this may
not be the case.
The possibility of alternative oestrogen sources in breast
cancer patients on treatment with aromatase inhibitors
should be considered. These could be enzymatic pathways
not inhibited by current drugs or, alternatively, that the
oestrogen synthesis could partly take place in compartments
not equilibrating with circulating androstenedione or not
penetrated by aromatase inhibitors. So far there is no direct
evidence pointing to any such a pathway. Alternatively,
plasma oestrogens could be derived from residual tissue oes-
trogens, like OeIS or lipoidal oestrogen conjugates (Larner et
al., 1992) which may have a slow turnover and could be
sustained in the tissue for a long time even when their
production is inhibited. While this possibility can not be
excluded, we found no correlation between plasma oestrogen
suppression and the duration of 4-hydroxyandrostenedione
treatment among patients investigated in this study. Results
by others (Dowsett et al., 1985b) as well as unpublished data
from our group suggest plasma oestrogens to be sustained
also in patients who have been on aminoglutethimide treat-
ment for more than 6 months. While it is not possible at this
stage to draw any conclusion considering possible sources of
these oestrogens, our finding of an internal consistency
between the relative suppression of plasma and urinary oes-
trogens in breast cancer patients treated with 4-hydroxy-
androstenedione add indirect support to a hypothesis that the
sustained plasma oestrogens are real oestrogens and not tech-
nical artefacts. This finding may have significant implications
for future studies on aromatase inhibitors in the treatment of
breast cancer.
The major metabolic pathways of oestrogens are hydroxy-
lation in the 2- and 16m-position (Bolt, 1979). Our results
revealed no significant change in the ratio of the 16m-
hydroxylated (16cx-OHOel and Oe3) or 2-hydroxylated (2-
OHOel) metabolites to Oel in the urine. Thus, in contrast to
aminoglutethimide (L0nning et al., 1989a; L0nning & Skul-
stad, 1989) 4-hydroxyandrostenedione does not seem to influ-
ence the major oestrogen metabolic pathways in vivo.
The metabolite 4-OHOel, like 2-OHOe2, was little sup-
pressed by treatment with 4-hydroxyandrostenedione. The
possibility exists that urinary 4-OHOel could arise from
aromatisation of 4-hydroxyandrostenedione. However, as the
urinary level of 4-OHOel before treatment was below the
detection limit of the method, the result should be interpreted
with caution. The contribution of 4-OHOel to total urinary
oestrogens before and during 4-hydroxyandrostenedione
treatment was 1.6% and 3.8% only. Thus, under any cir-
cumstance a direct production of 4-OHOe, from 4-hydroxy-
androstenedione most probably would not be of a magnitude
of biological importance and may not explain our finding of
sustained plasma and urinary oestrogens.
The reason why 2-OHOe2 is relatively moderately sup-
pressed remains unclear. At these low levels, the assay may
not be completely specific. The urinary concentration of this
metabolite was low. While there was a small increase in the
plasma Oe2/Oe1 ratio, the ratio of Oe2/Oe1 in urine was
slightly reduced. While previous investigations have suggested
a possible influence by 4-hydroxyandrostenedione on the 17p-
hydroxysteroid dehydrogenase in vitro (Brodie et al., 1982),
our results do not suggest any influence of 4-hydroxyandro-
stenedione on this enzyme in vivo. Neither is there any
obvious reason why 16P-OHOel was particularly effective
suppressed (mean suppression of 82%). However, it should
be considered that oestrogen metabolic enzymes have been
shown to be influenced by several exogenous factors (Con-
ney, 1986), and our current knowledge of the regulation of
these enzymes is incomplete.
Considering the plasma oestrogens, it may be noted that
the plasma Oe1/Oe1S ratio was reduced in 8/9 patients. This
contrasts the findings obtained with aminoglutethimide in
which case the Oe1/Oe1S ratio was elevated due to enhance-
ment of Oe1S metabolism (L0nning et al., 1989b). Our find-
ings seem to exclude any enhancement of Oe1S metabolism
by 4-hydroxyandrostenedione, but further studies are needed
to assess whether treatment with 4-hydroxyandrostenedione
causes a reduction in the Oe1/Oe1S ratio. If this should be the
case, it may provide information of clinical importance. Cur-
rent opinion in the literature is that there is no evidence of a
direct secretion of plasma Oe1S in postmenopausal women,
as circulating Oe1S seems to be accounted for by production
from plasma Oel and Oe2 (Longcope et al., 1972; Ruder et
al., 1972; Lonning et al., 1989a). However, it should be
recalled that patients on treatment with aromatase inhibitors
have plasma oestrogens markedly lower than other post-
menopausal women. Accordingly, while a small secretion of
Oe1S could be difficult to detect in postmenopausal women in
general, it could be of importance in patients having their
major oestrogen production pathways blocked by an aroma-
tase inhibitor. More studies are needed to evaluate this
phenomenon, but our findings underline the importance of
measuring plasma Oe,S in concert with Oel and Oe2 in
patients treated with aromatase inhibitors.
Conclusions
4-Hydroxyandrostenedione suppresses plasma and urinary
oestrogens in breast cancer patients, but the finding that bothBREAST CANCER TREATMENT WITH 4-HYDROXYANDROSTENEDIONE 397
plasma and urinary oestrogens remained at levels 30-50% of
their control values supports the hypothesis that alternative
oestrogen sources may exist in breast cancer patients. In
contrast to aminoglutethimide, 4-hydroxyandrostenedione
does not seem to have any major influence on the major
pathways of oestrogen metabolism.
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